Nektar Therapeutics (NKTR)

33.29
NASDAQ : Health Technology
Prev Close 34.62
Day Low/High 33.09 / 35.17
52 Wk Low/High 29.22 / 69.76
Avg Volume 1.53M
Exchange NASDAQ
Shares Outstanding 174.31M
Market Cap 6.03B
EPS 4.00
P/E Ratio 8.79
Div & Yield N.A. (N.A)
ImaginAb Announces Immuno-Oncology License And Clinical Trial Collaboration With Nektar Therapeutics

ImaginAb Announces Immuno-Oncology License And Clinical Trial Collaboration With Nektar Therapeutics

Nektar will use ImaginAb's CD8 ImmunoPET technology to accelerate the development of its investigational immuno-oncology medicines

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of Nektar securities between November 11, 2017 through...

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Nektar Therapeutics, Inc. Investors

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Nektar Therapeutics, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Nektar Therapeutics, Inc.

NKTR NOTICE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors Of Important Deadline In Class Action Seeking Investor Losses - NKTR

NKTR NOTICE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors Of Important Deadline In Class Action Seeking Investor Losses - NKTR

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nektar Therapeutics (NASDAQ:NKTR) from November 11, 2017 through October 2, 2018, inclusive (the "Class Period") of the important December 31, 2018 lead plaintiff...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR) of the December 31, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that...

Once Again It Is Breadth That Has My Eye

Breadth continues to outperform for now.

Kessler Topaz Meltzer & Check, LLP - Reminds Investors Of Securities Fraud Class Action Lawsuit Against Nektar Therapeutics

Kessler Topaz Meltzer & Check, LLP - Reminds Investors Of Securities Fraud Class Action Lawsuit Against Nektar Therapeutics

The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") on behalf of purchasers of Nektar securities between November 11, 2017...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMRC, ERA, HCI, MRO, PAA, PRPH, QDEL, SRE, TSLA Downgrades: ALRM, APEI, ASH, AVNS, CHUY, CTLT, HCLP, KE, MB, NKTR, NTB, TTWO Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm

NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR).

INVESTOR ACTION REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTOR ACTION REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...

INVESTOR ACTION ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTOR ACTION ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...

Scott Scott Attorneys At Law LLP Alerts Investors To Securities Class Action Against Nektar Therapeutics (NKTR)

Scott Scott Attorneys At Law LLP Alerts Investors To Securities Class Action Against Nektar Therapeutics (NKTR)

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and...

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ:NKTR) from November 11, 2017 through October 2, 2018, inclusive (the "Class Period").

Nektar Therapeutics Becomes #47 Most Shorted S&P 500 Component, Replacing Expeditors International Of Washington

Nektar Therapeutics Becomes #47 Most Shorted S&P 500 Component, Replacing Expeditors International Of Washington

The most recent short interest data has been released for the 10/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Behind the Selloff: Cramer's 'Mad Money' Recap (Thursday 10/4/18)

Behind the Selloff: Cramer's 'Mad Money' Recap (Thursday 10/4/18)

Jim Cramer lists the things we need to see before the bear backs off and the market regains its footing.

Anheuser-Busch InBev, Alteryx, Walker & Dunlop: 'Mad Money' Lightning Round

Anheuser-Busch InBev, Alteryx, Walker & Dunlop: 'Mad Money' Lightning Round

Jim Cramer weighs in on Anheuser-Busch InBev, Alteryx, Walker & Dunlop, Kratos Defense & Security, Johnson Controls, Nektar Therapeutics, Align Technology.

The New #48 Most Shorted S&P 500 Component: Nektar Therapeutics

The New #48 Most Shorted S&P 500 Component: Nektar Therapeutics

The most recent short interest data has been released for the 09/28/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

INVESTOR ALERT: Investigation Of Nektar Therapeutics Announced By Holzer & Holzer

INVESTOR ALERT: Investigation Of Nektar Therapeutics Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) complied with the federal securities laws.

Stitch Fix Tumbles; Nektar Finally Adds a Woman to Board -- ICYMI

Stitch Fix Tumbles; Nektar Finally Adds a Woman to Board -- ICYMI

Here's what you need to know now for Tuesday, Oct. 2.

U.S.-Canada Trade Deal, Tesla, Women on Company Boards - 5 Things You Must Know

U.S.-Canada Trade Deal, Tesla, Women on Company Boards - 5 Things You Must Know

U.S. stock futures rise sharply after the U.S. reaches an agreement with Canada to revamp the North American Free Trade Agreement; Tesla soars after CEO Elon Musk settles with the SEC; California bill requires women on company boards.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXL, BIG, DK, FOSL, NFG, NKTR, SRC, TGH, UTSI Downgrades: AIRG, AXAS, HPP, PAA, QDEL, RAD Initiations: FND, RETA, TOCA Read on to get TheStreet Quant Ratings' detailed report:

Nektar Therapeutics Takes Over #53 Spot From Leggett & Platt

Nektar Therapeutics Takes Over #53 Spot From Leggett & Platt

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Nektar Therapeutics has taken over the #53 spot from Leggett & Platt, Inc. , according to ETF Channel.

Nektar Is the One S&P 500 Company Without a Woman Director

Nektar Is the One S&P 500 Company Without a Woman Director

Nektar Therapeutics remains the only S&P 500 company without a woman on the board, according to BoardEx, a relationship mapping service of TheStreet.

Tech Alone Can't Save the Rally: Cramer's 'Mad Money' Recap (Tuesday 6/5/18)

Tech Alone Can't Save the Rally: Cramer's 'Mad Money' Recap (Tuesday 6/5/18)

Jim Cramer says the tech titans are leading the way, but out side of the tech sector, very few stocks are following.

Hasbro, Dropbox, Carlyle Group: 'Mad Money' Lightning Round

Hasbro, Dropbox, Carlyle Group: 'Mad Money' Lightning Round

Jim Cramer weighs in on Hasbro, Dropbox, Carlyle Group, Corning, Banco Santander, Goldman Sachs, Edwards Lifesciences, J. Jill and more.

ASCO's Big Winner: Loxo Oncology

ASCO's Big Winner: Loxo Oncology

Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics shares got destroyed on Monday. Here is why.

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

Jim Cramer takes a look at CVS Health, Prestige Brands, LendingTree, Valeant Pharmaceuticals, Nektar Therapeutics, Kirkland Lake and more.

Buffett's Optimism Rules: Cramer's 'Mad Money' Recap (Monday 5/7/18)

Buffett's Optimism Rules: Cramer's 'Mad Money' Recap (Monday 5/7/18)

Jim Cramer says Warren Buffett is the greatest investor, and his optimism has suffused trading and has been justified.

Nektar Therapeutics Moves Up In Analyst Rankings, Passing Thermo Fisher Scientific

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Nektar Therapeutics has taken over the #12 spot from Thermo Fisher Scientific Inc , according to ETF Channel. Below is a chart of Nektar Therapeutics versus Thermo Fisher Scientific Inc plotting their respective rank within the S&P 500 over time (NKTR plotted in blue; TMO plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

TheStreet Quant Rating: C (Hold)